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Abstract
Background: The risk of metastasis and the survival in patients with primary extremity soft tissue sarcomas is
worse when tumour size is large and the grade of malignancy is high. Such tumours may receive chemotherapy
and/or radiation therapy (RTX) for optimising local control. Irradiation can either be applied preoperatively or
after tumour resection. The question arises if the kind of RTX in the absence of chemotherapy influences the
outcome concerning local control, metastatic disease, survival and complications.
Methods: We retrospectively reviewed the clinical outcome of 233 patients with a primary extremity soft tissue
sarcoma treated between 1990 – 2000 with a mean follow-up of 35.8 (4–120) months in our institute. 41 patients
had high grade, deep and large tumours (>8 cm), an AJCC stage III (no evidence of metastasis prior to treatment)
and were treated with limb salvage surgery and irradiation but stayed without additional chemotherapy. Two
groups of patients were compared: the first group received postoperative RTX after tumour resection (n = 33);
the second group was treated with preoperative RTX (n = 8). Both groups did not differ concerning clinical
parameters. We analysed primary and secondary outcomes.
Results: 56% (23/41) of the population developed metastatic disease, 24% (10/41) local recurrence. The risk of
metastasis was higher in the group with preoperative irradiation (p = 0.046). The overall (p = 0.0248) and relapse
free survival (p = 0.104) were worse in this group. The delay to tumour resection amounted 8 weeks on average
in the preoperative group. Local control was not different (p = 0.38) in both study groups. Wound infections and
other combined therapy related complications were equally distributed (p = 0.22).
Conclusion: Without chemotherapy there remains a high risk of metastasis in AJCC grade 3 patients. In high
risk patients treated without chemotherapy the elapsed time to tumour resection after preoperative radiation
might contribute to the development of metastasis. This outcome may support the thesis that a combination of
RTX and offensive multimodal treatment protocols is advantageous in such a subset of patients
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Background
Since chemotherapy unlike in bone sarcomas is consid-
ered less effective in soft tissue sarcomas, wide resection
and postoperative RTX with 60–66 Gy for optimizing
local control is the standard treatment for such high grade
tumours [1-7]. Irradiation can be administered before,
during or after excision of the primary tumour with
entirely acceptable local control rates of 70–100% [4,6,8-
20]. The advancement of when to apply irradiation still
remains a controversy [7,21-26]. Furthermore, the impact
of local recurrence on overall survival is still not clear [4].
Some centres use irradiation for preoperative down stag-
ing of the tumour making limb salvage procedures appli-
cable [23] or for reduction of the radiation dose and field
size [27-29].
Development of metastasis is the most limiting event in
sarcomas [21,23,26,30,31] and is dependent on tumour
size and grade [13]. Heise et al. [32] reported a risk of 65%
for metastasis in high grade and large extremity soft tissue
sarcomas. Local recurrence is unlikely a major source of
metastasis [33]. With this in mind, this study focuses on a
group of patients with high grade, deep and large extrem-
ity soft tissue sarcomas which leveled identical values in
all clinical parameters but differed only in the way when
RTX was applied, either preoperative or postoperative. It
was analyzed if one therapy is advantageous in such a
population.
Methods
Between 1990 and 2000 a total of 233 patients were
treated for an extremity soft tissue sarcoma at the Univer-
sity Hospital Muenster, Department of Orthopaedic Sur-
gery. Data regarding tumour stage, grade, site, size, and
depth, time to treatment initialisation, surgical margin,
radiotherapy, local control and relapse-free respectively
overall survival were evaluated by review of the hospital
and office records. If this was not possible direct contact
with the referring physicians or patients was established.
Follow-up data was successfully obtained on all patients.
Patients were excluded from this analysis for the following
reasons: primary metastasized tumour (AJCC stage IV),
secondary malignancy, low grade, superficial or small
tumour (<8 cm), patients with chemotherapy or prior
radiotherapy or patients without primary limb salvage
surgery. Furthermore, all rhabdomyosarcomas were
excluded due to different treatment protocols. The study
protocol was presented to the local ethics committee.
Since we exclusively dealt with retrospectively and anony-
mously acquired data no official approval was necessary.
Using these criteria we reviewed 41 patients aged 18–77
(48 ± 17) years with a primary, nonmetastatic, high grade,
deep and large soft tissue sarcoma of the extremities who
received limb salvage surgery and RTX either preopera-
tively or postoperatively. The average length of follow-up
was 35.8 (4–120) months. All included patients were
staged no longer than 4 weeks prior to biopsy showing no
evidence of metastatic disease. The elapsed time from
biopsy to initialisation of therapy averaged 8.5 days in the
postoperative group and 7.8 days in the preoperative
group (p = 0.42, Mann-Whitney-U).
Since 1990 the principles of surgical management were
standardized using anatomical terms of compartment sur-
gery as described by Enneking et al. [34]. All surgical resec-
tions were performed by a musculoskeletal oncologic
surgeon.
Applying radiotherapy preoperatively or postoperatively
was decided individually after review of all imaging stud-
ies and interdisciplinary discussion with the involved col-
leagues and patients.
In this analysis, two patient groups were retrospectively
studied. The first group was treated with postoperative
RTX after tumour resection. The second group received
preoperative irradiation. The distribution of these 41 sar-
comas concerning histological type, anatomic site,
tumour size, age, sex, resection margin and stage is pre-
sented in Table 1 and Table 2. The most underlying dis-
ease was malignant fibrous histiocytoma (n = 18) in 44%
of all cases.
The mean total radiation dose administered to all 41
patients amounted to 56.1 Gy. The mean preoperative
radiation dose was 50 (48–51) Gy applied over a mean
duration of 35 days. Preoperative irradiation was initial-
ized 5–11 days after biopsy. The planning target volume
for preoperative radiotherapy included the primary
tumour with a safety margin of usually 5–7 cm in longitu-
dinal and 2 cm in axial direction. The elapsed time from
initialisation of preoperative RTX to tumour resection was
delayed by 8 (7 to 9) weeks on average compared with the
postoperative radiation group.
Tumour resection in the postoperative group followed 5–
14 days after biopsy. The mean postoperative radiation
dose was 60 (58–66) Gy. 1.8–2.0 Gy were applied 5 days
a week for a total of 6–8 weeks. Postoperative radiother-
apy was begun after completion of primary wound heal-
ing no later than 4 weeks after tumour resection. It was
delayed in case of marked cutaneous reactions and wound
complications. The planning target volume for postopera-
tive radiotherapy included the primary tumour volume
with a safety margin of 5–7 cm in longitudinal and 2 cm
in axial direction including scars and drain site for up to
50 Gy and a boost of 10–16 Gy to the initial tumour vol-
ume and an additional margin of 2 cm. CircumferentialBMC Cancer 2006, 6:160 http://www.biomedcentral.com/1471-2407/6/160
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limb irradiation and unnecessary irradiation of joints and
healthy tissue was avoided.
The resected tumour specimen was histologically analysed
by the Gerhard-Domagk-Institute of Pathology at the Uni-
versity Hospital Muenster for final diagnosis as to his-
topathological type, grade and resection margin. Grading
was based on degree of tumour differentiation, mitoses
and necrosis [35]. Pathological evaluation was used to
determine tumour size and the amount of tumour necro-
sis. The extent of histological necrosis in the resected
tumour was graded according to the criteria of Willet et al.
[36]: Grade 1: <50% necrosis, Grade 2: 50–80% necrosis,
Grade 3: >80% necrosis. On average one block per cm of
the largest tumour diameter was evaluated by routine his-
tology (H&E stain). The amount of tumour necrosis was
described in percentage of the evaluated tumour area.
Complications of the combined therapy (irradiation and
surgery) were evaluated (Table 3). Complications were
defined as operatively treated delayed wound healing,
persistent lymph edema or pathological nonmetastatic
fracture of the radiated extremity without prior partial
bone resection.
All sarcomas were staged using the American Joint Com-
mittee on Cancer (AJCC) staging system. Standard soft-
ware (SPSS for Windows, version 11.5.1) was used for
statistical analysis. In order to determine patient survival
Kaplan-Meier curves were plotted. Survival estimates were
performed for overall survival, relapse-free survival, local
and distant control using mean and standard deviation
with 95% confidence intervals (CI). The log rank test was
used to compare Kaplan-Meier curves. Additionally, the
chi square test and Mann-Whitney-U test were used in
order to evaluate the association between two variables.
Results
I. Overall survival
The overall survival of the entire study group (n = 41) was
52.6% after 5 years and 39.3 % after 10 years (Fig. 1). The
mean survival was 68 months (s ± 8, 95% CI 53–84). The
Kaplan-Meier-analysis (Fig. 2) showed a significant differ-
ence in overall survival between the patient group who
Table 1: Summary of patients' diagnoses
diagnosis patients
malignant fibrous histiocytoma 18
leiomyosarcoma 8
liposarcoma 7
neurogenous sarcoma 4
synovial sarcoma 4
total: 41
Table 2: Summary of study group patient data
Radiotherapy
preoperative Postoperative
cases 8 33
mean age (years) 40 ± 8.4 47 ± 3.1
sex
male 2 23
female 6 10
tumour size (cm) 11.8 (8–19) 12.0 (8.5–20)
AJCC stage III 8 33
resection margin
marginal 4 (50%) 18 (55%)
wide 4 (50%) 15 (45%)
elapsed time from biopsy to tumour resection 
(days)
7.8 (5–11) 8.5 (5–14)
site
proximal upper extremitiy 2 5
distal upper extremity 1 1
proximal lower extremitiy 5 24
distal lower extremity 0 3BMC Cancer 2006, 6:160 http://www.biomedcentral.com/1471-2407/6/160
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had received radiotherapy preoperatively and the group
who was treated with postoperative irradiation (p =
0.0248, log rank) favoring the postoperative group. At the
2.5-year time point, overall survival for patients receiving
preoperative radiotherapy was 37.5% (s ± 17) versus
69.7% (s ± 8) for the postoperative radiation group and at
the 5-year time point 18.8% (s ± 16) versus 56.0% (s ± 9).
The average survival time of these patients who were
treated with postoperative radiotherapy amounted to 75
months (s ± 9, 95% CI 58–92). In contrast, the patients
who underwent preoperative irradiation survived 31
months (s ± 9, 95% CI 13–49) on average.
II. Relapse free survival (RFS)
In the preoperative radiation group 7 of 8 patients
(87.5%) developed a disease relapse, 6 during the first
year after tumour resection (metastasis), one patient after
46 months (metastasis), one patient developed metastasis
after 2 months and local recurrence after 3 months.
Among the patients receiving postoperative radiation the
number of disease relapses was 22 (66.6%). The RFS for
patients with preoperative irradiation was 25% (s ± 15) at
2.5-years time point versus 48.5% (s ± 9) for the postop-
erative radiation group. On average, patients who received
irradiation after tumour resection survived 50 months (s
± 9, 95% CI 33–67) in complete remission compared with
Overall survival for patients with preoperative (grey line)  versus postoperative radiotherapy (black line) Figure 2
Overall survival for patients with preoperative (grey line) 
versus postoperative radiotherapy (black line).
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Table 3: Combined therapy related complications
Complication preoperative group postoperative group total
Wound healing disorder 2 3 5
Pathological fracture 0 2 2
Lymph edema 1 3 4
Wound healing disorders had to be treated by surgery in 25% in the preoperative radiation group and in 9% in the postoperative radiation group (p 
= 0.22, chi square). Pathological fractures following irradiation were only present in the postoperative group (6%). A lymph edema occurred in 
12.5% (preoperative group) and 9% (postoperative group).
Overall survival of the entire collective (n = 41) Figure 1
Overall survival of the entire collective (n = 41).
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19 months (s ± 7, 95% CI 6–32) in the preoperative radi-
ation group (Fig. 3). Despite this trend a significant differ-
ence between both patient groups concerning relapse-free
survival could not be demonstrated (p = 0.104, log rank).
III. Metastasis
Overall, 23 patients (56.1%) developed distant metas-
tases in both patient groups, 18 (43.9%) remained free of
any metastases. The number of metastases in the preoper-
ative radiation group was 7 (87.5%) and in the postoper-
ative group 16 (49.5%). In the following square table
(Table 4) a significant higher risk of metastases could be
demonstrated for patients who had received preoperative
irradiation (p = 0.046, chi square). The average metastasis
time (time from diagnosis to metastasis) for both studied
patient groups amounted to 15.61 (3–64) months. In the
preoperative group 6 patients suffered metastatic disease
in the first year after tumour resection (2, 5, 5, 6, 8 and 12
months) and one after 46 months. On average, patients
with preoperative radiotherapy developed distant metas-
tasis about 5 months earlier than patients who had under-
gone irradiation after tumour resection: the average
metastases time was 12 (5–46) months with preoperative
versus 17 (3–64) months with postoperative irradiation
(p = 0.72, Mann-Whitney-U). Margin status (p = 0.68, chi
square) and local recurrence (p = 0.24, chi square) did not
influence the development of metastatic disease. The clin-
ical features of preoperative and postoperative treated
patients who developed distant metastasis are displayed
in Tables 5 and 6.
IV. Local recurrence and local recurrence free survival
The total number of local recurrences was 10 (24.4%). In
9 of 33 patients (30%) who underwent postoperative
radiotherapy local recurrence was diagnosed after an aver-
age time (from diagnosis to local recurrence) of 18 (6–46)
months. Patients with preoperative radiotherapy had
equal local control (p = 0.38, chi square). Only one
patient (12.5 %) developed local recurrence after 3
months respectively (Table 7). The overall average local
recurrence time was 16 (3–46) months. The margin status
of either marginal or wide resection did not influence the
development of local recurrence, 7/22 recurrences with
marginal, 3/19 recurrences with wide resection (p = 0.23,
chi square). The metastasis rate was independent of the
local control status of each group (p = 0.24, chi square).
The local control status did not influence the overall sur-
vival (p = 0.45, log rank). Patients with a local recurrence
had a mean survival of 77 (s ± 14, 95% CI 49–104)
months and patients without a local recurrence had a
mean survival of 66 (s ± 9, 95% CI 48–83) months. Actu-
arial analysis of the local recurrence-free survival of
patients did not reveal a significant difference between the
preoperative and postoperative group: the proportion of
patients free of local recurrence after 5-years for the preop-
erative radiation group was 87.5% versus 77.5% for the
postoperative patients (p = 0.85, log rank). The mean
local recurrence free survival was 91 (s ±, 95% CI 76–105)
months in the postoperative group and 58 (s ± 7, 95% CI
44–71) months after preoperative radiation. Local relapse
was treated by resection with limb sparing surgery (6) or
salvage amputation (2) and in two cases of multiple
metastases palliatively.
The amount of tumour necrosis in cases with by preoper-
ative irradiation was less than 50% in 5/8 patients and
50–80% in the other 3/8 cases. There was no correlation
between amount of necrosis and the development of
metastasis or local recurrence. However, a definite distinc-
tion between original and radiation induced tumour
necrosis was not possible since in most cases only a small
biopsy for the establishment of the tumour diagnosis
could be compared with the final resection specimen.
Relapse-free survival for patients with preoperative (grey  line) versus postoperative radiotherapy (black line) Figure 3
Relapse-free survival for patients with preoperative (grey 
line) versus postoperative radiotherapy (black line).
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Discussion
Although RTX can cause transient or permanent loss of
lower limb function [4,24] it is regarded to improve local
control of high grade soft tissue sarcomas. This enables
the surgeon to perform limb sparing surgery with the
same results concerning local tumour control as with rad-
ical resection or amputation. Compared with a 50–70%
relapse free survival of nonirradiated patients [4,8,19,37]
the success rate after RTX (70–100%) is much higher
[3,6,7,12-15,17,18,28,31,38]. Whether to apply irradia-
tion preoperatively or after tumour resection has been
matter of debate in previous studies [7,21,24,25].
Preoperative radiation may be indicated if tumour size is
very big (>10 cm), if the localization is close to vital struc-
tures and radical resection otherwise is needed [11,13,21-
23,39,40]. The histological response to preoperative radi-
otherapy has been more favorable in large and high grade
tumours [13,21,36].
Preoperative radiation may still be useful for patients with
tumours not amendable to a limb salvage procedure due
to proximity of neurovascular structures [22,40]. In these
cases, brachytherapy can also be an alternative [16]. Pre-
operative radiation has been reported to be beneficial in
tumours after a shell out procedure resulting in an intral-
esional margin [22].
The theoretical advantages of preoperative irradiation
include decreased intraoperative seeding of viable tumour
cells in the operative field, sterilization of lymph node
metastasis outside the operative field, a smaller tumour
volume due to necrosis with formation of a pseudo cap-
sule facilitating surgical resection [22,23,29,36] and a
reduced toxicity with smaller median radiation dose and
field size [27] which is important since Yang et al. (1998)
reported about transient lower limb strength and
decreased range of motion in patients after postoperative
radiation with 63 Gy on average. Also, preoperative irradi-
ation seems to offer lesser late radiation morbidity by
diminished fibrosis, joint stiffness and edema [41].
Disadvantages are an increased number of wound infec-
tions [7,11,13,22,25,42,43] with a possible detrimental
effect on patient function [24] and other complications
[2,13,44].
Concerning local control a positive outcome of preopera-
tive administered irradiation is reported by Barkley et al.
(1988) [11], Brant et al. (1990) [39] and Sadoski et al.
(1993) [28]. Suit et al. [13] compared preoperative versus
postoperative radiation for soft tissue tumours and found
no difference in overall survival but local control of large
tumours was improved by preoperative irradiation. Suit
and Spiro (1994) [19] reported a local success rate of
100% and 79% of 15 cm and 20 cm large tumours after
Table 5: Clinical features of patients treated with preoperative radiotherapy
Nr. Age Sex Site Size Diag Margin FU/m Met/m Met/s status
27 35 F 2 13 3 marginal 10 5 Lung DOD
8 1 6 0 M 181m a r g i n a l 1 1 5M u l t i D O D
2 0 3 6 0 F481W i d e 5 9 4 6 M u l t i D O D
206 48 F 4 13 5 Wide 13 6 Multi DOD
331 77 F 1 19 3 Wide 6 2 Multi DOD
3 4 2 2 6M 3 1 21 m a r g i n a l 6 58 L u n g N O D
355 54 F 4 10 1 Wide 14 12 multi DOD
Average tumour size was 12 cm. Average follow-up was 25 months. Pat. 27 and 342 underwent thoracotomy for lung metastasis resection. Pat. 331 
developed local recurrence one month after multiple metastases under palliative treatment.
Table 4: Metastasis: incidence in preoperative versus postoperative irradiation group
metastasis
radiotherapy No yes
postoperative 17 (51.5%) 16 (48.5%)
preoperative 1 (12.5%) 7 (87.5%)
total 18 (43.9%) 23 (56.1%)
Metastatic disease was more likely to occur (p = 0.046) in the preoperative radiation therapy group. Most of the metastases (83%) occurred in 
multiple localisations almost simultaneously (n = 11) or in the lung (n = 8). Three times metastasis to lymph nodes (13%) and once to bone (4%) was 
noted.BMC Cancer 2006, 6:160 http://www.biomedcentral.com/1471-2407/6/160
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preoperative radiation whereas a rate of only 50% and
67% was achieved with postoperative irradiation. Cheng
et al. (1996) [22] compared preoperative with postopera-
tive RTX in similar patient groups and did not find signif-
icant differences concerning local control and survival.
More decisive for local control than the kind of irradiation
is a correct tumour resection [28]. A positive resection
margin deteriorates local control significantly [28, 45].
Karakousis and Zografos (2002) [46] and Karakousis et al.
(1986) [1] treated tumours with wide resection margins
with surgery alone and tumours with a margin <2 cm with
additional irradiation of 45–60 Gy. The 5-year local recur-
rence rate was 7–19% and 17–24%, respectively. This dis-
plays the potential of RTX to improve local control in
problematic cases. The difference in local failure between
wide and marginal resection with and without radiation
concerning to Alho et al. (1989) [47] was 8% to 10 or
37%. Marginal resection alone has a convincing high risk
and increased local failure rate [45]. Our local control rate
in the two observed groups was not statistically different
(p = 0.38). The resection margins were equally distributed
in both groups. Local relapse was treated by resection (six
cases) or salvage amputation (two cases) and palliatively
in two cases of multiple metastases.
Table 7: Local recurrence: preoperative versus postoperative therapy group
local recurrence
radiotherapy no Yes
postoperative 24 (70%) 9 (30%)
preoperative 7 (87.5%) 1 (12.5%)
total 31 (76%) 10 (24%)
There was no statistical significance (p = 0.38, chi square) in local control between the two examined groups. Local recurrence was treated with 
limb sparing surgery (n = 6), salvage amputation (n = 2) and palliatively in 2 cases of previous multiple metastasis.
Table 6: Clinical features of patients treated with postoperative radiotherapy
Nr. Age Sex Site Size Diag Margin FU/m Met/m Met/s status
43 1 M 493M a r g i n a l 1 6 3L u n g D O D
30 33 M 4 18 4 Wide 23 11 Multi DOD
63 55 M 2 12 1 Wide 23 14 Lung DOD
64 60 M 4 10 1 Wide 44 11 Lung NOD
82 67 M 4 8.5 1 Marginal 15 3 Multi DOD
1 3 7 6 1M 1 1 01 M a r g i n a l 3 23 0L u n g D O D
144 63 M 4 20 1 Wide 6 4 Lung DOD
145 68 M 5 11.5 1 Marginal 81 64 Lymph NOD
160 21 M 4 11 2 Marginal 31 21 Multi DOD
1 6 5 3 1F 2 1 52 M a r g i n a l 1 53 M u l t i D O D
178 32 M 4 10 2 Wide 18 16 Multi DOD
190 58 M 4 12 3 Marginal 24 12 Multi DOD
198 54 F 1 13 2 Marginal 120 6 Lung NOD
227 71 F 4 12 5 Marginal 39 38 Multi DOD
239 27 M 2 9.5 5 Wide 33 31 Lymph DOD
328 31 M 2 10 3 Marginal 8 4 Os DOD
Average tumour size was 12 cm. Average follow-up was 33 months. Pat. Nr. 63, 64 and 198 underwent thoracotomy for lung metastasis resection. 
Pat. 64 developed local recurrence (treated with limb sparing surgery) 2 months prior to metastasis. Pat. 137 developed local recurrence after 6 
months (treated with limb sparing surgery) and metastatic disease 24 months later. Pat. 190 developed local recurrence two months after 
metastatic disease occurred and palliative treatment had been initiated. Pat. 82, 145 and 239 were resected for regional lymph node metastasis. Pat. 
82 and 239 developed progredient disease with further metastasis under palliative treatment.
Abbreviations: Sex: F = female, M = male site: 1 = upper extremity 2 = pelvis 3 = groin 4 = thigh 5 = popliteal fossa 6 = shank diagnosis: 1 = 
malignant fibrous histiocytoma 2 = leiomyosarcoma 3 = liposarcoma 4 = synovial sarcoma 5 = neurogenous sarcoma
FU/m: Follow-up/months
Met/m: Manifestation of metastatic disease/months after tumour resection
Met/s: Anatomical localisation of metastasis
status: DOD = died of disease NOD = no evidence of diseaseBMC Cancer 2006, 6:160 http://www.biomedcentral.com/1471-2407/6/160
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Local control status has moderate influence on the devel-
opment of metastasis [33, 45, 48, 49]. Metastatic disease
is the most serious and limiting event in sarcomas
[21,23,26,29,30,32]. Suit et al (1988) [13] reported a 60%
risk of metastatic disease in 15–20 cm large extremity soft
tissue sarcomas. In our study group (n = 41) with compa-
rable tumour size 56% of the patients developed distant
metastasis although preoperative staging in all patients no
later than 4 weeks prior to treatment was negative. The
preoperative radiotherapy group was associated with 7/8
(87.5%) and the postoperative group with 16/33 (49.5%)
cases of metastatic disease (p= 0.046, chi square). Occur-
rence of metastasis was not influenced by surgical margin
(p = 0.68) or local control status (p = 0.24). The high per-
centage of metastatic disease caused a nonsignificant
worse relapse free survival of the preoperative radiation
group (p= 0.104). A similar outcome has earlier been
reported by Cheng et al. (1996) [22] also as a tendency in
a restricted group of their patients favouring the relapse
free survival of the postoperative radiation group. Virkus
et al. (2002) [23] reported 48% metastasis of their preop-
erative group and a local control rate of 86%. Wanebo et
al. (1995) [30] reported 98.5% local control rate but 38%
metastases after preoperative radiation despite simultane-
ous doxorubicin based chemotherapy. Current prospec-
tive trials use chemotherapy to improve distant disease-
free survival resulting in a significant improvement of
75% versus 44% compared to a historical control group
[26]. The combination of chemotherapy with regional
hyperthermia has shown promising results [50].
In a prospective randomised study of preoperative versus
postoperative RTX by O'Sullivan et al. (2002) [25]
regional and distal failure rates were identical but in this
study low grade (17%) and superficial (16–21%) tumours
were included. Nevertheless, this strong study suggests
that the results of our retrospective study are not universal
valid. An acknowledged deficiency of our study might be
the preselection bias inherent in all review studies making
validity and reliability of the results questionable.
Although we did not intend to preselect patients for any
of the two examined groups our patients are not equally
proported (33-8) and smaller than other reported series.
Despite, they are restricted to a well-defined cohort of
patients treated in a uniform manner and relatively well
balanced (see Table 1, 2). Average age, stage, tumour size,
depth, anatomic localisation and the resection margin
were equal in both groups. In addition, our study group
quite apparently displays an antiquated therapy regime
for in this group despite a high risk tumour no chemother-
apy was used. Chemotherapy today is a widely accepted
and important part of all randomised evidence-based
treatment protocols. We decided to enrol only patients
who did not receive chemotherapy to exclude any possi-
ble influence of this treatment on survival and the inci-
dence of metastasis in order to have a unique statement
about the possible influence of radiotherapy.
An average loss of time from initialization of preoperative
irradiation to tumour resection of 5 weeks and additional
3 weeks to allow the soft tissue to recover [23] can be
expected. The loss of time to surgical resection with viable
tumour in situ when irradiation is not fully effective might
deteriorate distant disease control. Willett et al. (1987)
[36] could find >80% necrosis in 69% of his patients with
large tumours >10 cm after preoperative radiation. Robin-
son et al. (1992) [40] showed in 60% of their preoperative
radiated patients a response with tumour reduction but
without clinical correlation. Other experimental and radi-
ographic studies report that a reduction in tumour vol-
ume may only be achieved in 40–60% with even tumour
progression in 12–15% [39]. Pitson et al. (2004) [51]
stated that preoperative radiation reduced tumour volume
(-59%) in liposarcoma but was ineffective in diminishing
tumour size in other entities (MFH, +7% volume). Hew et
al. (1994) [52] demonstrated only 26% of other than
liposarcoma tumours with >80% necrosis. Our study
group had mainly <50% tumour necrosis after preopera-
tive RTX unrelated to further clinical outcome. The value
of tumour necrosis estimation for radiosensivity and the
clinical course of different entities remains arguable [53].
Another problem is that negative staging does not rule out
occult micro metastasis. This might bias our findings con-
cerning metastasis after radiotherapy. At least, this prob-
lem affects both study groups.
Conclusion
Without chemotherapy there remains a high risk of metas-
tasis in AJCC grade 3 extremity soft tissue sarcoma
patients. Pre- or postoperative radiation seems to offer
equal local control. When no chemotherapy is applied the
elapsed time to tumour resection after preoperative radia-
tion might contribute to the development of metastasis
especially when the response to therapy is low. This out-
come may support the thesis that a combination of RTX
and offensive multimodal treatment protocols is advanta-
geous in such high risk patients.
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